4/A//SEC Filing
BELVIN MARCIA 4/A
Accession 0001610717-25-000020
CIK 0001501989other
Filed
Feb 9, 7:00 PM ET
Accepted
Feb 10, 5:58 PM ET
Size
12.5 KB
Accession
0001610717-25-000020
Insider Transaction Report
Form 4/AAmended
BELVIN MARCIA
SVP, Chief Scientific Officer
Transactions
- Award
Common Stock
2025-02-04+35,000→ 210,648 total - Award
Common Stock
2025-02-04+57,500→ 268,148 total - Award
Stock Option (Right to Buy)
2025-02-04+115,000→ 115,000 totalExercise: $0.86Exp: 2035-02-03→ Common Stock (115,000 underlying) - Award
Stock Option (Right to Buy)
2025-02-04+150,000→ 150,000 totalExercise: $0.86Exp: 2035-02-03→ Common Stock (150,000 underlying)
Footnotes (6)
- [F1]The Form 4 filed by the Reporting Person on February 6, 2025 incorrectly reflected the number of securities acquired in Box 4 of Table I and Box 5 of Table II and consequently the amount beneficially owned reflected in Box 5 of Table I and Box 9 of Table II. The number of securities acquired and the amount beneficially owned following reported transactions has been adjusted in this Form 4/A to correct the aforementioned errors. Except as otherwise noted in this footnote, all other information disclosed in the Reporting Person's original Form 4 was accurately reported.
- [F2]Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2026, subject to the Reporting Person continuing as a service provider through each such date.
- [F3]Constitute RSUs for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 50% of the RSUs vest annually on March 15 of each year, with the first 50% vesting on March 15, 2026, subject to the Reporting Person continuing as a service provider through each such date.
- [F4]Includes 201,666 RSUs.
- [F5]1/48th of the shares subject to the option vest on each monthly anniversary measured from February 4, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.
- [F6]1/24th of the shares subject to the option vest on each monthly anniversary measured from the Vesting Commencement Date, such that 100% of the shares subject to the option will be fully vested and exercisable on the second anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.
Documents
Issuer
CytomX Therapeutics, Inc.
CIK 0001501989
Entity typeother
Related Parties
1- filerCIK 0001970752
Filing Metadata
- Form type
- 4/A
- Filed
- Feb 9, 7:00 PM ET
- Accepted
- Feb 10, 5:58 PM ET
- Size
- 12.5 KB